Published in J Exp Med on February 01, 1952
Interactions between rabbit polymorphonuclear leucocytes and staphylococci. J Exp Med (1959) 17.17
Phagocytin: a bactericidal substance from polymorphonuclear leucocytes. J Exp Med (1956) 14.38
Community-associated meticillin-resistant Staphylococcus aureus. Lancet (2010) 9.07
The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br J Exp Pathol (1957) 7.04
The behavior of virulent and avirulent staphylococci in the tissues of normal mice. J Exp Med (1956) 6.31
The phagocytosis and inactivation of staphylococci by macrophages of normal rabbits. J Exp Med (1960) 6.09
Bacteremia: a consideration of some experimental and clinical aspects. Yale J Biol Med (1954) 4.46
Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction. J Clin Invest (1975) 4.45
Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest (2009) 3.24
Studies on bacteriemia. I. Mechanisms relating to the persistence of bacteriemia in rabbits following the intravenous injection of staphylococci. J Exp Med (1956) 3.21
Fate of non-virulent group A streptococci phagocytized by human and mouse neutrophils. J Exp Med (1957) 3.19
Intracellular survival of staphylococci. J Exp Med (1959) 3.00
Nonenteric toxins of Staphylococcus aureus. Microbiol Rev (1979) 2.95
Further observations on the behavior of staphylococci within human leukocytes. J Exp Med (1960) 2.89
Observations on the nature of staphylococcal infections. Bull N Y Acad Med (1959) 2.57
The egestion of phagocytized particles by leukocytes. J Exp Med (1953) 2.56
Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1979) 2.42
Studies on bacteriemia. III. The blood stream clearance of Escherichia coli in rabbits. J Exp Med (1957) 2.33
A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS One (2008) 2.12
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature (2015) 2.04
Electron microscopic study of phagocytosis of staphylococcus by human leukocytes. II. Virulent and non-virulent staphylococci. J Bacteriol (1956) 2.01
The effect of an NADH oxidase inhibitor (hydrocortisone) on polymorphonuclear leukocyte bactericidal activity. J Clin Invest (1970) 1.91
Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother (2006) 1.89
agr-Dependent interactions of Staphylococcus aureus USA300 with human polymorphonuclear neutrophils. J Innate Immun (2010) 1.77
Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J Biol Med (1967) 1.75
Studies on bacteriemia. II. Further observations on the granulocytopenia induced by the intravenous injection of Staphylococci. J Exp Med (1957) 1.74
An experimental analysis of the curative action of penicillin in acute bacterial infections. III. The effect of suppuration upon the antibacterial action of the drug. J Exp Med (1956) 1.72
Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1990) 1.68
Rapid neutrophil destruction following phagocytosis of Staphylococcus aureus. J Innate Immun (2010) 1.62
Staphylococcus epidermidis strategies to avoid killing by human neutrophils. PLoS Pathog (2010) 1.60
Fate of staphylococci within human leukocytes. J Exp Med (1960) 1.55
Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol (2011) 1.54
A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol (2011) 1.53
The site of action of the Staphylococcus alpha toxin. J Exp Med (1961) 1.51
Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nat Rev Microbiol (2011) 1.50
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother (2003) 1.47
Treatment of experimental staphylococcal infection with rifampin. Antimicrob Agents Chemother (1972) 1.44
Cellular immunity. Bacteriol Rev (1960) 1.43
Phagocytosis of Staphylococcus aureus by macrophages exerts cytoprotective effects manifested by the upregulation of antiapoptotic factors. PLoS One (2009) 1.41
Titrations of antibodies against alpha-haemolysin and the components of staphylococcal leucocidin in human subjects following immunization. Br J Exp Pathol (1962) 1.40
Phagocytosis, with particular reference to encapsulated bacteria. Bacteriol Rev (1960) 1.37
What is a Staphylococcus? Bacteriol Rev (1962) 1.34
Resistance to infection in burned patients. Ann Surg (1963) 1.33
Studies on the pathogenesis of staphylococcal infection. II. The effect of non-specific inflammation. J Exp Med (1961) 1.27
Catalase and superoxide dismutase activities in virulent and nonvirulent Staphylococcus aureus isolates. J Clin Microbiol (1985) 1.21
Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J Mol Med (Berl) (2010) 1.21
Neutrophil bleaching of GFP-expressing staphylococci: probing the intraphagosomal fate of individual bacteria. J Immunol (2009) 1.18
Phagocytosis by human leucocytes. I. Effect of fibrin on phagocytosis of staphylococci and of encapsulated pneumococci by normal human leucocytes. J Clin Invest (1954) 1.17
STUDIES ON THE PATHOGENESIS OF STAPHYLOCOCCAL INFECTION : I. THE EFFECT OF REPEATED SKIN INFECTIONS. J Exp Med (1961) 1.16
Growth of Bordetella pertussis in tissue culture. J Bacteriol (1959) 1.10
The pathogenesis of primary cicatricial alopecias. Am J Pathol (2010) 1.09
Virulence and immunity of Staphylococcus aureus BB and certain deficient mutants. Infect Immun (1978) 1.08
Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother (2001) 1.07
Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis and induces programmed necrosis. J Immunol (2014) 1.06
A privileged intraphagocyte niche is responsible for disseminated infection of Staphylococcus aureus in a zebrafish model. Cell Microbiol (2012) 1.03
A NET Outcome. Front Immunol (2012) 1.00
Staphylococcal PknB as the first prokaryotic representative of the proline-directed kinases. PLoS One (2010) 0.97
Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria. Antimicrob Agents Chemother (1984) 0.95
Phagocytic and bactericidal activity of human neutrophils against two isolates of Group B streptococci Type Ic of differing pathogenicity. Br J Exp Pathol (1981) 0.95
Infection of rabbit knee joints after intra-articular injection of Staphylococcus aureus. Comparison with joints injected with Staphylococcus albus. Am J Pathol (1970) 0.94
Staphylococcus aureus protein A promotes immune suppression. MBio (2013) 0.91
STUDIES ON THE PATHOGENESIS OF STAPHYLOCOCCAL INFECTION : III. THE EFFECT OF TISSUE NECROSIS AND ANTITOXIC IMMUNITY. J Exp Med (1961) 0.91
Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures. J Orthop Res (2010) 0.90
Phagocytosis and killing of Staphylococcus aureus by human neutrophils. J Innate Immun (2014) 0.89
Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob Agents Chemother (2014) 0.87
Clonal expansion during Staphylococcus aureus infection dynamics reveals the effect of antibiotic intervention. PLoS Pathog (2014) 0.84
How methicillin-resistant Staphylococcus aureus evade neutrophil killing. Curr Opin Hematol (2015) 0.80
In Vitro Anti-inflammatory and Immunomodulatory Effects of Ciprofloxacin or Azithromycin in Staphylococcus aureus-Stimulated Murine Macrophages are Beneficial in the Presence of Cytochalasin D. Inflammation (2015) 0.80
Electron microscopic study on phagocytosis of staphylococci by mouse peritoneal macrophages. Infect Immun (1978) 0.80
Intra-cellular Staphylococcus aureus alone causes infection in vivo. Eur Cell Mater (2013) 0.79
Impact of LY146032 on Streptococcus (Enterococcus) faecalis translocation in mice. Antimicrob Agents Chemother (1988) 0.79
Killing of oxacillin-exposed staphylococci in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1980) 0.79
Effect of highly purified coagulase and culture filtrate on virulence and immunity of a coagulase-negative mutant of staphylococcus aureus BB. Infect Immun (1983) 0.78
Evasion of Neutrophil Killing by Staphylococcus aureus. Pathogens (2016) 0.77
Staphylococcal adaptation to diverse physiologic niches: an overview of transcriptomic and phenotypic changes in different biological environments. Future Microbiol (2015) 0.77
Killing of Staphylococcus aureus in murine macrophages by chloroquine used alone and in combination with ciprofloxacin or azithromycin. J Inflamm Res (2015) 0.76
Biofilm-Forming Methicillin-Resistant Staphylococcus aureus Survive in Kupffer Cells and Exhibit High Virulence in Mice. Toxins (Basel) (2016) 0.76
[Treatment with antibiotic agents with special reference to their relation to otorhinolaryngology]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd (1967) 0.75
Resistance-increasing activity of bacterial lipopolysaccharides and their subfractions towards levan-enhanced infections. Br J Exp Pathol (1962) 0.75
The effect of some antibiotics on coccal infection in mice. Br J Exp Pathol (1953) 0.75
Mechanisms of resistance of staphylococci grown in plasma to polymorph bactericidins. J Hyg (Lond) (1984) 0.75
Interaction of Staphylococci with Human B cells. PLoS One (2016) 0.75
The struggle against sepsis. Yale J Biol Med (1959) 0.75
THE ACTION OF VITAL STAINS BELONGING TO THE BENZIDINE GROUP. Science (1914) 19.48
THE PROTECTION OF PATHOGENIC MICROORGANISMS BY LIVING TISSUE CELLS. J Exp Med (1916) 18.60
The protection of intracellular brucella against streptomycin alone and in combination with other antibiotics. J Lab Clin Med (1951) 4.77
THE COAGULASE TEST FOR STAPHYLOCOCCI AND ITS CORRELATION WITH THE RESISTANCE OF THE ORGANISMS TO THE BACTERICIDAL ACTION OF HUMAN BLOOD. J Clin Invest (1942) 4.66
STUDIES ON THE MECHANISM OF RECOVERY IN PNEUMONIA DUE TO FRIEDLADER'S BACILLUS : III. THE ROLE OF "SURFACE PHAGOCYTOSIS" IN THE DESTRUCTION OF THE MICROORGANISMS IN THE LUNG. J Exp Med (1947) 4.03
STUDIES ON THE MECHANISM OF IMMUNITY IN TUBERCULOSIS : THE MOBILIZATION OF MONONUCLEAR PHAGOCYTES IN NORMAL AND IMMUNIZED ANIMALS AND THEIR RELATIVE CAPACITIES FOR DIVISION AND PHAGOCYTOSIS. J Exp Med (1939) 3.37
Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc (1954) 5.58
Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest (1959) 4.73
Studies on bacteriemia. I. Mechanisms relating to the persistence of bacteriemia in rabbits following the intravenous injection of staphylococci. J Exp Med (1956) 3.21
Treatment of enterococcal endocarditis and bacteremia; results of combined therapy with penicillin and streptomycin. Am J Med (1951) 3.10
Further observations on the behavior of staphylococci within human leukocytes. J Exp Med (1960) 2.89
Observations on the nature of staphylococcal infections. Bull N Y Acad Med (1959) 2.57
Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc (1954) 2.39
Host mechanisms which act to remove bacteria from the blood stream. Bacteriol Rev (1960) 2.34
Studies on bacteriemia. III. The blood stream clearance of Escherichia coli in rabbits. J Exp Med (1957) 2.33
THE PHAGOCYTIC ACTIVITY OF POLYMORPHONUCLEAR LEUKOCYTES OBTAINED FROM PATIENTS WITH DIABETES MELLITUS. J Lab Clin Med (1964) 2.00
The emergence of pseudotuberculosis in rats given cortisone. J Exp Med (1952) 2.00
Effects of adrenocorticotropic hormone and cortisone in patients with tuberculosis. J Clin Invest (1951) 1.99
Protection of pathogenic staphylococci by phagocytes. Trans Assoc Am Physicians (1956) 1.95
Factors relating to the virulence of Staphylococci. II. Observations on four mouse-pathogenic strains. J Exp Med (1962) 1.93
Observations on the immunology of pathogenic staphylococci. Yale J Biol Med (1962) 1.76
Studies on bacteriemia. II. Further observations on the granulocytopenia induced by the intravenous injection of Staphylococci. J Exp Med (1957) 1.74
The current problem of Staphylococcal infections. Ann Intern Med (1956) 1.70
Studies on influenza in the pandemic of 1957-1958. I. An epidemiologic, clinical and serologic investigation of an intrahospital epidemic, with a note on vaccination efficacy. J Clin Invest (1959) 1.69
The changing pattern of life-threatening microbial disease. N Engl J Med (1959) 1.61
Fate of staphylococci within human leukocytes. J Exp Med (1960) 1.55
Factors relating to the virulence of Staphylococci. III. Antibacterial versus antioxic immunity. J Exp Med (1962) 1.53
Separation of hypophosphite, phosphite and phosphate by anion-exchange chromatography. J Chromatogr (1962) 1.38
THE DYNAMICS OF RETICULOENDOTHELIAL BLOCKADE. J Exp Med (1965) 1.36
The influence of pyrazinamide-isoniazid on M. tuberculosis in animals and man. Trans Assoc Am Physicians (1954) 1.27
Studies on bacteriemia. V. The effect of simultaneous leukopenia and reticuloendothelial blockade on the early blood stream clearance of staphylococci and Escherichia coli. J Exp Med (1961) 1.20
CLINICAL AND LABORATORY OBSERVATIONS ON TYPE E BOTULISM IN MAN. Medicine (Baltimore) (1964) 1.19
Staphylococcal immunity: production of staphylococcal hemagglutinins in rabbits receiving staphylococcal vaccine. Proc Soc Exp Biol Med (1960) 1.18
An analysis of the effects of penicillin on an experimental infection produced by penicillin-resistant staphylococci. J Lab Clin Med (1960) 1.17
The evolution of tuberculous lesions in the guinea pig during administration of adrenocorticotropic hormone (ACTH) or cortisone. Am Rev Tuberc (1951) 1.15
Resistance of tubercle bacilli to pyrazinamide in vivo. Am Rev Tuberc (1956) 1.10
The syndrome of fatal influenza virus pneumonia. Trans Assoc Am Physicians (1958) 1.09
Studies on bacteriemia. IV. Alterations in rabbit mortality associated with aging of a culture of Escherichia coli. J Exp Med (1958) 1.00
Staphylococci and man. JAMA (1962) 0.97
The effects of corticosteroids upon tuberculosis and pseudotuberculosis. Ann N Y Acad Sci (1953) 0.95
Neoplastic involvement of the meninges with low cerebrospinal fluid glucose concentrations simulating tuberculous meningitis. Am Rev Tuberc (1954) 0.95
Oral treatment of subacute bacterial endocarditis with phenoxymethyl penicillin (penicillin V). N Engl J Med (1957) 0.93
The efficacy of modified oral penicillin therapy of pneumococcal lobar pneumonia. Bull Johns Hopkins Hosp (1951) 0.92
BOTULISM, VINTAGE 1963. Ann Intern Med (1964) 0.92
Preservation of cultures of M. tuberculosis by freezing. Am Rev Tuberc (1951) 0.90
Studies on novobiocin, a new antimicrobial agent. Antibiotic Med Clin Ther (New York) (1956) 0.89
The detection of tubercle bacilli in mouth wash specimens by the use of membrane filter cultures. Am Rev Tuberc (1955) 0.87
Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy. Am Rev Tuberc (1954) 0.85
Current status of therapy in acute osteomyelitis. JAMA (1962) 0.85
Novobiocin: a laboratory investigation. Antibiotic Med Clin Ther (New York) (1956) 0.84
The toxicity of viomycin in humans. Am Rev Tuberc (1951) 0.83
Concurrent administration of pyridoxine and isoniazid. Am Rev Tuberc (1956) 0.83
Tuberculostatic activity of blood and urine from animals given gliotoxin. J Immunol (1950) 0.82
Effects of ACTH on tuberculosis in humans. J Clin Invest (1950) 0.81
The survival of staphylococci within human leucocytes. Bull N Y Acad Med (1952) 0.81
Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide. Am Rev Tuberc (1955) 0.81
Dynamics of antituberculous chemotherapy. Am Rev Tuberc (1956) 0.81
Aortic valve perforation in bacterial endocarditis. Circulation (1961) 0.80
STUDIES ON EXPERIMENTAL BACTEREMIA AND RETICULOENDOTHELIAL FUNCTION. Trans Am Clin Climatol Assoc (1964) 0.79
Recent advances in streptomycin therapy. Am J Med (1949) 0.78
Antimicrobial therapy: the concurrent administration of two drugs. Am J Med Sci (1958) 0.76
Quantitative observations on the pattern of emergence of resistance to isoniazid. Am Rev Tuberc (1954) 0.76
Agranulocytosis associated with novobiocin administration: report of a case. Ann Intern Med (1957) 0.75
The relation of growth dispersion to growth inhibition of M. tuberculosis by subtilin and other chemotherapeutic agents. J Clin Invest (1948) 0.75
Relation of dosage to streptomycin toxicity. Ann Otol Rhinol Laryngol (1948) 0.75
ACCREDITATION AND THE COUNCIL ON MEDICAL EDUCATION. Fed Bull (1964) 0.75
The relation of protein-binding to the pharmacology and antibacterial activity of penicillins X, G, dihydro F and K. J Clin Invest (1947) 0.75
Relationship of type of growth of M. tuberculosis to antituberculous activity of subtilin. Proc Soc Exp Biol Med (1950) 0.75
Discontinuous therapy with penicillin. J Am Med Assoc (1949) 0.75
Complications of the use of antimicrobial drugs. N Y State J Med (1955) 0.75
The prophylactic use of antibiotics. Med Times (1960) 0.75
A panel discussion. The prophylactic use of antibiotics. Med Times (1960) 0.75
Therapy of infections. Bull N Y Acad Med (1958) 0.75
Current developments in the treatment of bacterial endocarditis. N Y State J Med (1953) 0.75
CLINICAL AND LABORATORY MANIFESTATIONS OF TYPE E BOTULISM IN MAN. Trans Assoc Am Physicians (1964) 0.75
Problems in the use of antimicrobial agents. Conn State Med J (1958) 0.75
Short-term penicillin and dihydrostreptomycin therapy of streptococcal endocarditis: results of the treatment of thirty-five patients. Am J Med (1958) 0.75
Therapeutic uses of gamma globulin. Am J Med (1948) 0.75
Bacterial endocarditis. Tex State J Med (1961) 0.75
Treatment of pneumonia. Am J Med (1948) 0.75
[Laboratory and clinical studies on isoniazid in the treatment of tuberculosis; a review of 16 months' experience]. Arch Med Cuba (1953) 0.75
IMMUNITY TO CLUMPING FACTOR-NEGATIVE STAPHYLOCOCCI. Antimicrob Agents Chemother (Bethesda) (1964) 0.75
Treatment of pneumonia with novobiocin. Antibiotic Med Clin Ther (New York) (1958) 0.75
TEACHING AND INFECTIOUS DISEASE. J Med Educ (1964) 0.75
[Not Available]. Am Clin (1949) 0.75
Influence of protein-binding on the interpretation of penicillin activity in vivo. Proc Soc Exp Biol Med (1947) 0.75
Staphylococcal infections. Dis Mon (1958) 0.75
The dynamics and immunology of the phagocytosis of staphylococci. Trans Assoc Am Physicians (1961) 0.75
A laboratory and clinical investigation of dihydrostreptomycin. Am Rev Tuberc (1948) 0.75
DIAGNOSIS AND TREATMENT OF BACTERIAL ENDOCARDITIS. Dis Mon (1964) 0.75
Staphylococcal disease on general medical services. Am J Nurs (1959) 0.75
Chronic recurrent nonhemolytic streptococcic endocarditis; report of a patient treated with penicillin and dihydrostreptomycin. AMA Arch Intern Med (1950) 0.75
The blood stream clearance of staphylococci in rabbits. Ann N Y Acad Sci (1956) 0.75
Histoplasma capsulatum endocarditis with major arterial embolism. Report of an apparent recovery. Arch Intern Med (1962) 0.75